MARKET

MBRX

MBRX

Moleculin Biotec
NASDAQ
4.140
-0.550
-11.73%
Closed 19:59 12/17 EST
OPEN
4.180
PREV CLOSE
4.690
HIGH
4.370
LOW
3.630
VOLUME
5.96M
TURNOVER
--
52 WEEK HIGH
91.25
52 WEEK LOW
3.630
MARKET CAP
8.56M
P/E (TTM)
-0.0741
1D
5D
1M
3M
1Y
5Y
1D
Buy Rating for Moleculin Biotech: Promising Progress with WP1066 in Pediatric Brain Tumors
TipRanks · 21h ago
Moleculin Biotech Reports Positive Phase 1 Trial Results
TipRanks · 1d ago
Moleculin Biotech announces results from Phase 1 trial of WP1066
TipRanks · 1d ago
Moleculin Biotech Data From Phase Clinical Study Of WP1066 Demonstrates Anti-Tumor Immune Responses To Treat Pediatric Recurrent Malignant Brain Tumors
Benzinga · 1d ago
Moleculin Reports Positive Phase 1 Results for WP1066 in Pediatric Brain Tumors
Reuters · 1d ago
MOLECULIN BIOTECH INC - WP1066 FOUND SAFE AND EFFECTIVE, WARRANTING PHASE 2 TRIAL
Reuters · 1d ago
Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors
Barchart · 1d ago
Moleculin Biotech Regains Nasdaq Compliance
TipRanks · 1d ago
More
About MBRX
Moleculin Biotech, Inc. is a Phase III clinical-stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing tumors and viruses. The Company is conducting a pivotal Phase III trial evaluating Annamycin, a non-cardiotoxic anthracycline, in combination with Cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia (AML). It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio, and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other transcription factors, and its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).

Webull offers Moleculin Biotech Inc stock information, including NASDAQ: MBRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MBRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MBRX stock methods without spending real money on the virtual paper trading platform.